Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.25
MDVN's Cash to Debt is ranked higher than
62% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. MDVN: 1.25 )
MDVN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.25

Equity to Asset 0.30
MDVN's Equity to Asset is ranked higher than
54% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. MDVN: 0.30 )
MDVN' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.99
Current: 0.3

-0.02
0.99
F-Score: 7
Z-Score: 13.74
M-Score: -1.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.87
MDVN's Operating margin (%) is ranked higher than
89% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. MDVN: 11.87 )
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27   Max: 66.67
Current: 11.87

-510.27
66.67
Net-margin (%) 6.05
MDVN's Net-margin (%) is ranked higher than
85% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. MDVN: 6.05 )
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58   Max: 37.65
Current: 6.05

-496.58
37.65
ROE (%) 16.54
MDVN's ROE (%) is ranked higher than
94% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. MDVN: 16.54 )
MDVN' s 10-Year ROE (%) Range
Min: -2940.27   Max: 4.99
Current: 16.54

-2940.27
4.99
ROA (%) 4.91
MDVN's ROA (%) is ranked higher than
89% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. MDVN: 4.91 )
MDVN' s 10-Year ROA (%) Range
Min: -73.93   Max: 4.69
Current: 4.91

-73.93
4.69
ROC (Joel Greenblatt) (%) 59.17
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. MDVN: 59.17 )
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -230657.14   Max: -47.79
Current: 59.17

-230657.14
-47.79
Revenue Growth (%) 58.60
MDVN's Revenue Growth (%) is ranked higher than
97% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. MDVN: 58.60 )
MDVN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 60
Current: 58.6

0
60
EBITDA Growth (%) -19.00
MDVN's EBITDA Growth (%) is ranked higher than
66% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. MDVN: -19.00 )
MDVN' s 10-Year EBITDA Growth (%) Range
Min: -22.5   Max: 154.6
Current: -19

-22.5
154.6
EPS Growth (%) 4.50
MDVN's EPS Growth (%) is ranked higher than
84% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. MDVN: 4.50 )
MDVN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 71
Current: 4.5

0
71
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MDVN Guru Trades in Q3 2013

Steven Cohen 1,900 sh (New)
Andreas Halvorsen Sold Out
» More
Q4 2013

MDVN Guru Trades in Q4 2013

Jim Simons 94,000 sh (New)
Steven Cohen 6,888 sh (+262.53%)
» More
Q1 2014

MDVN Guru Trades in Q1 2014

Mario Gabelli 15,046 sh (New)
John Burbank 3,173 sh (New)
Steven Cohen 216,962 sh (+3049.85%)
Jim Simons Sold Out
» More
Q2 2014

MDVN Guru Trades in Q2 2014

Mario Gabelli 25,046 sh (+66.46%)
John Burbank Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-06-30 Sold Out 0.01%$55.08 - $77.773 $ 96.1443%0
Mario Gabelli 2014-06-30 Add 66.46%$55.08 - $77.773 $ 96.1443%25046
Mario Gabelli 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 96.1431%15046
John Burbank 2014-03-31 New Buy0.01%$61.08 - $86.97 $ 96.1431%3173
George Soros 2012-03-31 Sold Out 0.1%$45.84 - $75.56 $ 96.1459%0
George Soros 2011-12-31 New Buy0.1%$15.79 - $48.8 $ 96.14188%50000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation Inc

Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and HomeAway Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc, and HomeAway Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 347.10
MDVN's P/E(ttm) is ranked higher than
84% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 347.10 )
MDVN' s 10-Year P/E(ttm) Range
Min: 254.58   Max: 344.87
Current: 347.1

254.58
344.87
P/B 51.41
MDVN's P/B is ranked higher than
58% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. MDVN: 51.41 )
MDVN' s 10-Year P/B Range
Min: 0.59   Max: 1848.25
Current: 51.41

0.59
1848.25
P/S 19.00
MDVN's P/S is ranked higher than
73% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. MDVN: 19.00 )
MDVN' s 10-Year P/S Range
Min: 4.54   Max: 563.33
Current: 19

4.54
563.33
PFCF 267.06
MDVN's PFCF is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 267.06 )
MDVN' s 10-Year PFCF Range
Min: 3.04   Max: 265.36
Current: 267.06

3.04
265.36
EV-to-EBIT 157.69
MDVN's EV-to-EBIT is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 157.69 )
MDVN' s 10-Year EV-to-EBIT Range
Min: 120.8   Max: 164.1
Current: 157.69

120.8
164.1
Current Ratio 4.76
MDVN's Current Ratio is ranked higher than
75% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. MDVN: 4.76 )
MDVN' s 10-Year Current Ratio Range
Min: 1.46   Max: 27.3
Current: 4.76

1.46
27.3
Quick Ratio 4.76
MDVN's Quick Ratio is ranked higher than
76% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. MDVN: 4.76 )
MDVN' s 10-Year Quick Ratio Range
Min: 1.46   Max: 27.3
Current: 4.76

1.46
27.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 291.34
MDVN's Price/Net Current Asset Value is ranked higher than
74% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. MDVN: 291.34 )
MDVN' s 10-Year Price/Net Current Asset Value Range
Min: 0.38   Max: 1558.67
Current: 291.34

0.38
1558.67
Price/Tangible Book 51.41
MDVN's Price/Tangible Book is ranked higher than
63% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. MDVN: 51.41 )
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 1152.75
Current: 51.41

0.3
1152.75
Price/Median PS Value 0.63
MDVN's Price/Median PS Value is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. MDVN: 0.63 )
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.29
Current: 0.63

0.15
2.29
Price/Graham Number 26.63
MDVN's Price/Graham Number is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MDVN: 26.63 )
MDVN' s 10-Year Price/Graham Number Range
Min: 21.54   Max: 21.54
Current: 26.63

Earnings Yield (Greenblatt) 0.60
MDVN's Earnings Yield (Greenblatt) is ranked higher than
52% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MDVN: 0.60 )
MDVN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 0.8
Current: 0.6

0.6
0.8
Forward Rate of Return (Yacktman) 0.02
MDVN's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. MDVN: 0.02 )
MDVN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: -0.3
Current: 0.02

-0.4
-0.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany
Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI (enzalutamide) capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which previously was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration, or FDA, for the post-docetaxel indication. The Company has obtained an exclusive, worldwide commercial license to a series of novel small molecules. The Company is conducting this program in collaboration with Astellas. Its business strategy is to use current GMP compliant contract manufacturers for manufacture of clinical supplies as well as for commercial supplies if required by its commercialization plans, and to transfer manufacturing responsibility to its collaboration partners when possible. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio Aug 15 2014 
Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and H Feb 02 2014 
Andreas Halvorsen Buys 2 Million Shares of Medivation Aug 22 2012 
Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, TER Feb 14 2012 
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 16,800 Shares Feb 11 2011 
Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence Patrick Machado sells 4,200 Shares Feb 08 2011 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 10,000 Shares Jan 20 2010 
Medivation Inc. (MDVN) Sr. Vice President and CFO Clarence Patrick Machado sells 20,000 Shares Dec 08 2009 
Medivation Inc. (MDVN) President and CEO David Hung sells 25,000 Shares Dec 08 2009 

More From Our Partners
Fast Money Halftime Report Final Trade From September 12 Sep 12 2014 - BENZINGA

More From Other Websites
Your first trade for Monday Sep 12 2014
[video] FMHR Final Trade: MDVN, C, NUE Sep 12 2014
Medivation Eyes Blockbuster As Cancer Drug Gets An OK Sep 11 2014
Medivation-Astellas' Xtandi's Label Expanded by FDA Sep 11 2014
Stifel Raises Medivation Inc Price Target Sep 11 2014
U.S. FDA approves expanded use of Medivation prostate cancer drug Sep 10 2014
U.S. FDA okays expanded use of Medivation prostate cancer drug Sep 10 2014
Medivation Resumes Trading After Xtandi Receives FDA Approval Sep 10 2014
U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with... Sep 10 2014
U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With... Sep 10 2014
Medivation Prostate Cancer Drug Secures Expanded FDA Label Sep 10 2014
Medivation Announces Participation at Upcoming Investor Conference Aug 25 2014
Can Medivation (MDVN) Run Higher on Strong Earnings Estimate Revisions? Aug 25 2014
MEDIVATION, INC. Financials Aug 15 2014
Medivation Jumps on Q2 Earnings Beat, Outlook Encourages Aug 11 2014
Medivation (MDVN) Jumps: Stock Adds 7.5% in Session Aug 11 2014
Why Medivation (MDVN) Stock Is Gaining Today Aug 08 2014
Medivation Cancer Drug Fuels Beat, Swings To Profit Aug 08 2014
MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2014
Medivation Reports Second Quarter Financial Results and Provides Corporate Update Aug 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK